RealNose is a breakthrough AI-Bionano machine olfaction startup focused on harnessing artificial intelligence and bionanotechnology for innovative sensing solutions. Leveraging the extraordinary olfactory prowess exhibited by dogs, and DARPA-funded work led by one of the co-founders for MIT, RealNose is developing AI-trained, bioprogrammable olfactory sensors that map scent profiles and recognize patterns. Initially targeting early prostate cancer detection and Gleason scoring, RealNose aims to revolutionize diagnostic processes across the healthcare sector by providing a non-invasive, cost-effective, and highly accurate method for early disease detection.

Current prostate cancer detection methods, such as Prostate-Specific Antigen (PSA) blood tests, Digital Rectal Exam (DRE), and biopsies, are often invasive, expensive, and lack the necessary accuracy, leaving patients stressed and subjected to unnecessary, repeatedly injurious procedures.

RealNose develops a unique platform capable of identifying scent signatures, creating an AI-driven electronic device that mimics canine olfaction. Our technology leverages bionanomaterials, machine learning, and bioprogrammable receptors, allowing for high-accuracy trace odor detection. Initially, RealNose aims to offer a non-invasive and highly accurate method for prostate cancer detection and plans to expand to other types of cancer and conditions in the future. The solution's potential applications span from identifying contraband, explosives, and toxins, to monitoring biopharmaceutical fermenters and quality control of composite materials -amongst many other scent-profiling applications that RealNose platform can be trained to recognize.